Geode Capital Management
ATRA icon

Geode Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Geode Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$863K Buy
75,128
+8,982
+14% +$71.6K ﹤0.01% 3412
2026
Q1 		$313K Buy
66,146
+3,765
+6% +$23K ﹤0.01% 3756
2025
Q4 		$1.13M Buy
62,381
+1,855
+3% +$27.7K ﹤0.01% 3336
2025
Q3 		$867K Buy
60,526
+390
+0.6% +$4.49K ﹤0.01% 3431
2025
Q2 		$464K Buy
60,136
+1,457
+2% +$10.6K ﹤0.01% 3577
2025
Q1 		$349K Buy
58,679
+3,935
+7% +$34.4K ﹤0.01% 3671
2024
Q4 		$729K Buy
54,744
+8,024
+17% +$84.5K ﹤0.01% 3477
2024
Q3 		$380K Buy
46,720
+4,043
+9% +$34.6K ﹤0.01% 3694
2024
Q2 		$363K Sell
42,677
-43,667
-51% -$657K ﹤0.01% 3689
2024
Q1 		$1.5M Buy
86,344
+338
+0.4% +$6K ﹤0.01% 3224
2023
Q4 		$1.1M Buy
86,006
+2,943
+4% +$68.6K ﹤0.01% 3321
2023
Q3 		$3.07M Buy
83,063
+1,801
+2% +$80.2K ﹤0.01% 2889
2023
Q2 		$3.27M Buy
81,262
+4,679
+6% +$265K ﹤0.01% 2920
2023
Q1 		$5.55M Buy
76,583
+2,838
+4% +$275K ﹤0.01% 2590
2022
Q4 		$6.05M Buy
73,745
+2,892
+4% +$301K ﹤0.01% 2566
2022
Q3 		$6.7M Buy
70,853
+2,395
+3% +$269K ﹤0.01% 2515
2022
Q2 		$13.3M Buy
68,458
+1,214
+2% +$198K ﹤0.01% 2045
2022
Q1 		$15.6M Buy
67,244
+2,425
+4% +$772K ﹤0.01% 2053
2021
Q4 		$25.5M Buy
64,819
+5,906
+10% +$2.49M ﹤0.01% 1788
2021
Q3 		$26.4M Sell
58,913
-1,660
-3% -$595K ﹤0.01% 1764
2021
Q2 		$23.5M Buy
60,573
+3,796
+7% +$1.35M ﹤0.01% 1856
2021
Q1 		$20.4M Buy
56,777
+8,595
+18% +$3.8M ﹤0.01% 1864
2020
Q4 		$23.6M Buy
48,182
+5,645
+13% +$2.61M ﹤0.01% 1614
2020
Q3 		$13.8M Buy
42,537
+7,150
+20% +$2.43M ﹤0.01% 1770
2020
Q2 		$12.9M Buy
35,387
+2,278
+7% +$575K ﹤0.01% 1782
2020
Q1 		$7.04M Buy
33,109
+3,771
+13% +$1.2M ﹤0.01% 1946
2019
Q4 		$12.1M Buy
29,338
+1,478
+5% +$510K ﹤0.01% 1878
2019
Q3 		$9.83M Buy
27,860
+3,981
+17% +$1.49M ﹤0.01% 1943
2019
Q2 		$12M Buy
23,879
+2,043
+9% +$1.44M ﹤0.01% 1809
2019
Q1 		$21.7M Buy
21,836
+1,913
+10% +$1.78M 0.01% 1359
2018
Q4 		$17.3M Buy
19,923
+1,862
+10% +$1.73M 0.01% 1386
2018
Q3 		$18.7M Buy
18,061
+1,034
+6% +$1.01M 0.01% 1461
2018
Q2 		$15.6M Buy
17,027
+2,957
+21% +$3.18M ﹤0.01% 1539
2018
Q1 		$13.7M Buy
14,070
+6,196
+79% +$5.65M ﹤0.01% 1533
2017
Q4 		$3.56M Buy
7,874
+190
+2% +$70.2K ﹤0.01% 2417
2017
Q3 		$3.18M Buy
7,684
+147
+2% +$55.4K ﹤0.01% 2472
2017
Q2 		$2.64M Buy
7,537
+591
+9% +$228K ﹤0.01% 2571
2017
Q1 		$3.57M Buy
6,946
+290
+4% +$120K ﹤0.01% 2316
2016
Q4 		$2.36M Buy
6,656
+797
+14% +$337K ﹤0.01% 2531
2016
Q3 		$3.13M Buy
5,859
+350
+6% +$190K ﹤0.01% 2271
2016
Q2 		$3.1M Buy
5,509
+394
+8% +$189K ﹤0.01% 2199
2016
Q1 		$2.43K Sell
5,115
-175
-3% -$78.8K ﹤0.01% 2334
2015
Q4 		$3.49M Buy
5,290
+454
+9% +$343K ﹤0.01% 2125
2015
Q3 		$3.8M Buy
4,836
+2,259
+88% +$2.76M ﹤0.01% 2016
2015
Q2 		$3.4M Buy
2,577
+297
+13% +$341K ﹤0.01% 2163
2015
Q1 		$2.37M Buy
2,280
+873
+62% +$577K ﹤0.01% 2337
2014
Q4 		$941K Buy
+1,407
New +$859K ﹤0.01% 2882

Other funds holding ATRA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management's ATRA Position: Q2 2026 in Review

Geode Capital Management increased its Atara Biotherapeutics (ATRA) stake by 14% in Q2 2026, buying an estimated $71.6K and bringing the position to 75,128 shares worth $863K. The position accounts for ﹤0.01% of the portfolio, ranked #3412.

Geode Capital Management first reported a position in ATRA in Q4 2014 and has held it in 47 quarters since. The position peaked at $26.4M in Q3 2021. 21 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

  • Geode Capital Management held 75,128 shares of Atara Biotherapeutics worth $863K as of Q2 2026.
  • Geode Capital Management bought 8,982 Atara Biotherapeutics shares in Q2 2026, an estimated $71.6K.
  • Atara Biotherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3412 holding.
  • Geode Capital Management first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 47 quarters since.
  • Geode Capital Management's Atara Biotherapeutics position peaked at $26.4M in Q3 2021.
  • 21 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.